DUPILUMAB

Brand name:

• Dupixent®

Pharmaceutical company:

Sanofi-Aventis Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Asthma

PBAC Submission type:

Change to existing listing (Category 2)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2024

Related medicines:

--

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

10/04/2025

5Lodgement of required documentation:

22/04/2025

Acceptance of complete documentation:

Under consideration

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---